GW Pharmaceuticals PLC (NASDAQ:GWPH) has been assigned a consensus rating of “Buy” from the twelve research firms that are presently covering the company. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $141.92.

A number of analysts have recently issued reports on GWPH shares. Morgan Stanley raised their price target on shares of GW Pharmaceuticals PLC from $152.00 to $160.00 and gave the stock an “overweight” rating in a report on Sunday, September 25th. Goldman Sachs Group Inc. started coverage on shares of GW Pharmaceuticals PLC in a report on Friday, October 7th. They set a “buy” rating and a $189.00 price target for the company. Leerink Swann started coverage on shares of GW Pharmaceuticals PLC in a report on Tuesday, October 4th. They set an “outperform” rating and a $162.00 price target for the company. Numis Securities Ltd upgraded shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Friday, August 26th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $147.00 price target on shares of GW Pharmaceuticals PLC in a report on Monday, September 26th.

GW Pharmaceuticals PLC (NASDAQ:GWPH) opened at 128.53 on Tuesday. The firm’s market capitalization is $2.82 billion. GW Pharmaceuticals PLC has a 12 month low of $35.83 and a 12 month high of $137.88. The stock’s 50 day moving average price is $109.73 and its 200-day moving average price is $92.06.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.21) by $1.15. The business earned $3.10 million during the quarter, compared to the consensus estimate of $3.63 million. GW Pharmaceuticals PLC had a negative net margin of 409.40% and a negative return on equity of 26.26%. The business’s revenue was down 73.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.09) EPS. Equities analysts forecast that GW Pharmaceuticals PLC will post ($4.52) earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the company. Advisory Services Network LLC increased its stake in GW Pharmaceuticals PLC by 1,109.2% in the third quarter. Advisory Services Network LLC now owns 786 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 721 shares in the last quarter. IFP Advisors Inc increased its stake in GW Pharmaceuticals PLC by 15.3% in the first quarter. IFP Advisors Inc now owns 1,759 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 234 shares in the last quarter. Seven Eight Capital LLC increased its stake in GW Pharmaceuticals PLC by 216.7% in the first quarter. Seven Eight Capital LLC now owns 1,900 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 1,300 shares in the last quarter. Rothschild Investment Corp IL bought a new stake in GW Pharmaceuticals PLC during the second quarter worth approximately $200,000. Finally, HighTower Advisors LLC bought a new stake in GW Pharmaceuticals PLC during the second quarter worth approximately $203,000. 68.71% of the stock is currently owned by hedge funds and other institutional investors.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

5 Day Chart for NASDAQ:GWPH

Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.